Soricimed's proof-of-concept published in journal | BioTuesdays

You are here: Home / Briefs / Soricimed?s proof-of-concept published in journal

Closely-held Soricimed Biopharma has reported results from molecular imaging?that provided a proof-of-concept for the use of SOR peptides to detect and?potentially treat ovarian, breast, thyroid, prostate and colon cancer. The?findings have been published in PLOS ONE, an international, peer-reviewed,?online publication.

oricimed developed SOR peptides from Soricidin, a 54-amino acid peptide,?found in the paralytic venom of the northern short-tailed shrew. These?peptides, SOR-C13 and SOR-C27, are high-affinity antagonists of human TRPV6?channels that are up-regulated in a number of cancers.

The molecular imaging methods demonstrated the in vivo diagnostic potential?of SOR-C13 and SOR-C27 to target tumor sites in mice bearing ovarian and?prostate tumors, suggesting that these novel peptides may aid in the?diagnosis and treatment of TRPV6-rich tumors, such as those found in?ovarian, breast, thyroid, prostate and colon cancer, as well as certain?leukemia?s and lymphomas.

?Despite recent advances with identification, cancers such as ovarian,?remain difficult to detect and are typically identified only after they have?metastasized to other parts of the body, leading to low survival rates,??Jack Stewart, chairman and CSO, said in a statement.

He said that as calcium ion influx channels, termed TRPV channels, have?emerged as potential cancer biomarkers, exciting opportunities for the?development of improved tumor detection and targeted drug therapy have?opened up.

?We, at Soricimed, are developing peptide-drug conjugates that target these?tumors?our peptide binds to TRPV6 delivering its drug payload directly to?the tumor site, offering new diagnostic and therapeutic avenues for the?early detection and treatment of TRPV6-rich tumors,? he added.

Soricimed and the National Research Council of Canada collaborated on the?publication of the manuscript, titled ?In vivo detection of TRPV6-rich?tumors with anti-cancer peptides derived from soricidin.? The full?manuscript can be accessed here.

Filed under Briefs ? Tagged with cancer, Jack Stewart, northern short-tailed shrew, paralytic, PLoS ONE, SOR peptides, SOR-C13, SOR-C27, soricidin, Soricimed Biopharma, TRPV6, venom

Source: http://biotuesdays.com/2013/03/19/soricimeds-proof-of-concept-published-in-journal/

madonna give me all your luvin video roseanne barr president green party day 26 new hunger games trailer sasquatch david choe